MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Completed

• Conditions: Pulmonary Hypertension; Pulmonary Arterial Hypertension; Interstitial Lung Disease

• Registration Number: NCT02858791
• Lead Sponsor: Northwell Health

Brief Summary

The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.

Detailed Description

The investigators will test our hypothesis and accomplish our objectives by pursuing three Specific Aims:

To investigate the interrelationship between macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH with a working hypothesis that an increased release of MIF into the pulmonary vasculature during cardiopulmonary exercise changes the normal balance between plasma MIF and T4.

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2016-06-14
• Study First Submitted QC: 2016-08-03
• Study First Posted: 2016-08-08
• Primary Completion: 2017-12-21
• Study Completion: 2017-12-21
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-08
• Last Update Posted: 2018-01-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

• Subject must be at least 18 years of age and have confirmed pulmonary hypertension (PH) and interstitial lung disease (ILD).
• ILD was identified on high resolution computed tomography along with a total lung capacity (TLC) <70% of predicted value on pulmonary function tests (PFTs) with no evidence of pulmonary hypertension on echocardiogram.
• PAH group patients were defined as patients with a mean pulmonary artery pressure >25 mmHg at rest and a wedge pressure of <15 mmHg (millimeters of mercury), measured by right heart catheterization (WHO group I PAH).
• PH+ILD group, subjects with evidence of ILD on high resolution CT Scan and mean pulmonary artery pressure >25 mmHg on right heart catheterization.
• Patient with evidence of Chronic thromboembolic disease on CT angiogram and mean pulmonary artery pressure >25mmHg on right heart catheterization. (WHO group IV)
• Patient with Pulmonary Hypertension due to other conditions, such as Sarcoidosis, Gauchers disease, Hemolytic Anemia and Myeloproliferative disorders.
• Normal control group: Subjects without cardiopulmonary disease, with a normal PFT and ECG.

Exclusion Criteria

• Failure to obtain informed consent;
• Pregnancy
• Subjects with cardiopulmonary disease other than PH and ILD;
• Unexplained abnormal PFT, ECG, Routine blood/chemistries test
• History or existing other sever organ/system diseases
• Defined Acute pulmonary embolism
• Age < 18 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To examine the MIF-T4 relationship in patients before/after a standardized exercise challenge	up to 30 mins	Assess levels of the proinflammatory cytokine macrophage migration inhibitory factor (MIF) before/after standard exercise challenge

Trial Locations

Locations (1)

Northwell Health; 🇺🇸 New Hyde Park, New York, United States